Weight-Loss Injections in Knightsbridge: A Medical Safety Guide

What are weight-loss injections and how do they work?

"Weight-loss injections" usually means GLP-1 receptor agonists, prescription-only medicines that copy a gut hormone released after eating. They help people feel fuller, reduce appetite and slow stomach emptying. Some newer medicines also act on a second hormone, GIP. All are used alongside a reduced-calorie diet and increased physical activity.

Glucagon-like peptide-1 (GLP-1) is a hormone released by the gut when food arrives. It signals fullness to the brain, slows the rate at which the stomach empties, and helps the pancreas manage blood sugar. GLP-1 receptor agonists are engineered to last far longer than the natural hormone, so most weight-management products are injected just once a week. A dual GIP and GLP-1 receptor agonist acts on two hormone pathways involved in appetite and blood sugar.

The Medicines and Healthcare products Regulatory Agency (MHRA) points out that not every GLP-1 medicine is licensed for weight management; some are licensed only for type 2 diabetes. It also states clearly that these medicines should only be used by people who are overweight or have diabetes, not by people who want to lose weight for aesthetic or cosmetic purposes. The MHRA notes that it has not assessed their safety or effectiveness outside their licensed uses.

That scale of use is one reason regulators have repeatedly updated their safety advice, and why this guide focuses on eligibility, evidence and safety rather than on any particular product. At Levirgo, prescribing is only ever a possible outcome of a doctor-led weight management consultation, never the starting point.

Who is eligible? NICE guidance and BMI thresholds

NICE recommends GLP-1 medicines on the NHS for adults with a BMI of at least 35 and at least one weight-related condition, with a lower threshold for some groups. Thresholds are usually reduced by 2.5 for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. Private prescribing follows the medicines’ licences and clinical judgement.

Body mass index (BMI) is weight in kilograms divided by height in metres squared. The NHS classes a BMI of 25 to 29.9 as overweight and 30 or more as obese for most adults, and 23 to 27.4 as overweight and 27.5 or more as obese for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, who face health risks at a lower BMI. BMI cannot tell muscle from fat, so waist-to-height ratio is often checked too.

For tirzepatide, NHS England’s interim commissioning guidance sets a phased rollout over three years, prioritising people with the highest BMI and the most weight-related conditions (high blood pressure, abnormal blood fats, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes). The first group was people with a BMI of 40 or more and at least four of those conditions; NICE lists an expansion from around June 2026 to a BMI of 35 to 39.9 with four conditions, and from around March 2027 to a BMI of 40 or more with three.

How much weight do people lose? What the trials show

In the STEP 1 trial, adults lost an average of 14.9% of body weight over 68 weeks with weekly semaglutide 2.4 mg, compared with 2.4% on placebo. In SURMOUNT-1, weekly tirzepatide produced average losses of 15.0% to 20.9% over 72 weeks, depending on dose, compared with 3.1% on placebo.

Two points are easy to miss. First, every trial combined the medicine with a reduced-calorie diet and physical activity support; NICE’s semaglutide appraisal notes there is no evidence of effectiveness when it is used as a stand-alone treatment. Second, the placebo groups also lost weight with lifestyle support alone, and a meaningful minority of people on the active medicines lost less than 5%. That is why NICE builds a six-month review into both appraisals.

What happens when you stop weight-loss injections?

Most people regain weight after stopping. One year after withdrawal in the STEP 1 extension, participants had regained two-thirds of the weight they had lost, and cardiometabolic improvements moved back towards baseline. In SURMOUNT-4, people switched to placebo regained 14.0% of body weight over a year.

Obesity behaves like a long-term condition. When appetite-suppressing treatment stops, hunger signals return. In the STEP 1 extension analysis, 327 participants were followed for a year after treatment ended. Those who had taken the active medicine had lost an average of 17.3% of body weight by week 68, regained 11.6 percentage points by week 120, and ended with a net loss of 5.6%. The authors concluded that the findings confirm the chronic nature of obesity and suggest ongoing treatment is required to maintain improvements.

The withdrawal trials tell the same story from a different angle. In STEP 4, people who continued treatment after a 20-week run-in lost a further 7.9%, while those switched to placebo regained 6.9%. In SURMOUNT-4, 89.5% of those who continued tirzepatide kept at least 80% of their earlier loss, compared with 16.6% of those switched to placebo.

What are the side effects of weight-loss injections?

The most common side effects are nausea, vomiting, diarrhoea and constipation, usually mild to moderate and most noticeable when doses increase. Less common but serious risks include acute pancreatitis, severe dehydration and, very rarely with semaglutide, a sight-threatening eye condition. The MHRA had received 1,296 Yellow Card reports of pancreatitis by October 2025.

Stomach and bowel effects make up most Yellow Card reports the MHRA receives for these medicines. In STEP 1, 4.5% of people on the active medicine stopped because of gastrointestinal effects, compared with 0.8% on placebo. In SURMOUNT-1, adverse events led to stopping in 4.3% to 7.1% of those on tirzepatide, compared with 2.6% on placebo. Doses are therefore increased gradually; SURMOUNT-1 used a 20-week escalation period.

On mental health, the MHRA completed a comprehensive safety review and concluded that the available data do not support a causal link between GLP-1 medicines and depression, suicidal thoughts or suicide, while continuing to monitor. Anyone who notices a change in mood should still speak to their doctor. Suspected side effects, or a product you suspect is not genuine, can be reported through the MHRA Yellow Card scheme.

MHRA safety warnings: fake pens, pregnancy and surgery

The MHRA warns people never to buy GLP-1 medicines from beauty salons, social media or any seller without a prior consultation, reports counterfeit pre-filled pens, and says powder vials for mixing are not authorised. It also advises effective contraception during treatment, stopping before trying to conceive, and telling your anaesthetist before surgery.

According to the MHRA, legitimate GLP-1 medicines come as pre-filled injection pens or tablets. Counterfeit pre-filled pens that closely mimic licensed products have been reported. The only way to be sure a medicine is genuine is to obtain it from a legitimate pharmacy, including online pharmacies, against a prescription issued by a healthcare professional. You can check a Great Britain pharmacy on the General Pharmaceutical Council register.

Pregnancy, breastfeeding and contraception

The MHRA advises that anyone who could become pregnant should take steps to avoid pregnancy while using GLP-1 medicines, because there is not enough safety data in pregnancy, and animal studies have shown harm to the unborn foetus with some of these medicines. They should not be used while breastfeeding. If you think you might be pregnant, speak to a healthcare professional straight away.

Before any operation or procedure under general anaesthesia or deep sedation, tell your healthcare team, including the anaesthetist, that you take a GLP-1 medicine. Because it slows stomach emptying, it can increase the risk of stomach contents entering the airways, so instructions before the procedure may need to change. The MHRA advises not stopping treatment without first discussing it with your doctor.

Why a private prescription must start with a proper assessment

Weight-management medicines are classed as higher-risk medicines by the pharmacy regulator. Since February 2025, GPhC guidance has required prescribers to independently verify weight, height or BMI before online supply, rather than relying on a questionnaire. A proper assessment also screens for eating disorders, pregnancy, interacting medicines and conditions that make treatment unsafe.

The General Pharmaceutical Council (GPhC) updated its guidance for pharmacies providing services at a distance in response to concerns about unsafe online prescribing. Medicines used for weight management were added to the list of high-risk medicines needing extra safeguards. The GPhC is explicit that the prescriber must use a different way to verify what the person has told them, for example two-way communication, access to clinical records or contact with their GP. The same principles make sense for any private prescriber.

1. Measured, not self-reported

   Height, weight, BMI and waist measurement taken in clinic, with blood pressure. This is the simplest protection against inappropriate prescribing.

2. Full medical and medicines history

   Previous pancreatitis, stomach or bowel conditions, diabetes treatment, planned surgery, mental health and any current or past eating disorder, asked about sensitively.

3. Pregnancy and contraception discussion

   Plans for pregnancy, current contraception and whether a barrier or non-oral method is needed.

4. Blood tests where indicated

   For example HbA1c for blood sugar, kidney function or lipids, depending on your history.

5. Shared decision and consent

   An honest discussion of expected benefits, side effects, alternatives including lifestyle and NHS options, cost and the likelihood of regain on stopping.

6. Information sharing with your GP

   With your consent, your NHS GP is informed so your records are complete. If sharing is declined and that creates a safety risk, a responsible prescriber may decline to prescribe.

7. Scheduled reviews

   Regular reviews of weight, side effects, mood, nutrition and whether to continue, adjust or stop, in line with the six-month review principle used by NICE.

The General Medical Council’s prescribing guidance also asks doctors who are not a patient’s regular GP to seek consent to contact the GP when more information is needed, and to explain the risks if the patient refuses. At Levirgo, weight management sits within our private GP service, so the assessment is carried out as a medical consultation rather than a sales conversation.

How to protect muscle, nutrition and skin during weight loss

Some of the weight lost on GLP-1 medicines is lean tissue. A 2024 review found reported lean mass losses ranging from about 15% or less to 40% to 60% of total weight lost across studies. Adequate protein, regular resistance exercise, enough overall nutrition and regular reviews help protect muscle and wellbeing.

The review in Diabetes, Obesity and Metabolism explains that lean mass includes organs, bone and water as well as muscle, so a fall in lean mass is not the same as an equal fall in muscle. MRI-based studies suggest muscle changes may be broadly in line with the amount of weight lost, and muscle quality may improve. The authors still flag older age and more severe disease as situations where the risk of losing too much muscle needs careful attention.

• Protein at every meal, which becomes harder when appetite is low. A dietitian or clinician can suggest an individual target.
• Resistance exercise, such as weights, bands or body-weight exercises, on at least two days a week, as recommended in NHS physical activity guidelines for adults.
• Enough food overall. Eating very little can worsen fatigue, dizziness and muscle loss. The NHS suggests aiming to lose 0.5 to 1 kg a week when losing weight through lifestyle change.
• Fluids and fibre to help with constipation and to avoid dehydration if nausea reduces drinking.
• Reviews that look beyond the scales, including energy, strength, mood and waist measurement.

Health benefits do not depend on reaching an ideal weight. The NHS notes that losing 5% to 10% of body weight can improve health. Rapid or large weight loss can leave skin on the face, arms, abdomen and thighs looser, particularly as we age. Once weight has stabilised, some people explore non-surgical skin tightening for mild to moderate laxity, while significant excess skin usually needs a surgical opinion.

How much does a supervised weight-loss programme cost in London?

A private, medically supervised programme in London typically costs about £150 to £350 a month in total, depending on the medicine and dose prescribed, how often you are reviewed and whether blood tests are needed. Some people are eligible for NHS treatment, so it is worth checking NHS options before paying privately.

Beware of offers that lead with a low monthly price but skip in-person measurement, reviews or a plan for stopping, since those are the parts that keep treatment safe. If you would like to discuss whether medical weight management is appropriate for you, book a confidential consultation or contact the team with a question first.

How to choose a safe weight management provider

Choose a provider where a registered prescriber assesses you in a two-way consultation, measures you, reviews your history and medicines, explains risks and alternatives, shares information with your GP and supplies medicines through a GPhC-registered pharmacy. Avoid any seller offering GLP-1 medicines without a consultation.

1. Check who prescribes. Doctors can be checked on the GMC register, and pharmacist or nurse independent prescribers on the GPhC or NMC registers.
2. Check the pharmacy. Search the GPhC register for any Great Britain pharmacy supplying your medicine.
3. Expect questions. A safe provider asks about eating disorders, pregnancy, previous pancreatitis, other medicines and planned surgery.
4. Expect measurement. Weight, height or BMI should be independently verified, not simply typed into a form.
5. Expect follow-up. Reviews, a named contact for side effects, and a written plan for maintenance or stopping.
6. Check regulation. Independent doctors and clinics in England are regulated by the Care Quality Commission, and you can look up a provider on the CQC website.

Medical weight management at Levirgo in Knightsbridge

Levirgo is a doctor-led aesthetics, skin and private GP clinic at 6 Beauchamp Place, Knightsbridge, a few minutes from Harrods and Knightsbridge Underground station on the Piccadilly line. Weight management starts with a confidential medical assessment, and medicine is prescribed only where it is safe and clinically appropriate.

• Doctor and prescriber-led assessment with in-clinic measurements, history, medicines review and blood tests where indicated.
• Honest eligibility advice, including when NHS options, lifestyle support or no medicine at all is the better route.
• Gradual dosing and scheduled reviews, with guidance on protein, strength exercise and managing side effects.
• A written maintenance and step-down plan, not an open-ended prescription.
• Joined-up care: hormonal conditions such as PCOS, skin changes and body contouring can be discussed under one roof.
• Convenient for Belgravia, Chelsea, South Kensington residents and people working across central London.